Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ONCY

Oncolytics Biotech, Inc

Apr 16 • 04:00PM ET

1.06

-0.04 -3.64 %

Healthcare • Biotechnology • Canada • NASD

Peers: CRSP NTLA EDIT BLUE CLLS FATE IOVA ADAP PSTX TCRT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.23	Insider Own	-	Shs Outstand	108.02M	Perf Week	1.92%
Market Cap	123.09M	Forward P/E	-	EPS next Y	-0.19	Insider Trans	-	Shs Float	98.14M	Perf Month	6.98%
Enterprise Value	118.45M	PEG	-	EPS next Q	-0.04	Inst Own	3.29%	Short Float	6.30%	Perf Quarter	0.95%
Income	-21.37M	P/S	-	EPS this Y	12.09%	Inst Trans	0.74%	Short Ratio	4.39	Perf Half Y	-12.40%
Sales	0.00M	P/B	-	EPS next Y	1.49%	ROA	-197.73%	Short Interest	6.18M	Perf YTD	21.28%
Book/sh	-0.04	P/C	23.67	EPS next 5Y	16.21%	ROE	-11838.99%	52W High	1.51 -29.80%	Perf Year	86.62%
Cash/sh	0.04	P/FCF	-	EPS past 3/5Y	3.00% 6.32%	ROIC	-	52W Low	0.33 225.35%	Perf 3Y	-7.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.43% 8.21%	Perf 5Y	-64.55%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	25.51%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-73.67%
Dividend Ex-Date	-	Quick Ratio	1.12	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.08	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	1.12	EPS Q/Q	81.17%	SMA20	11.63%	Beta	1.21	Target Price	5.41
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	8.73%	Rel Volume	0.50	Prev Close	1.10
Employees	29	LT Debt/Eq	-	Earnings	Mar 30 AMC	SMA200	-0.16%	Avg Volume	1.41M	Price	1.06
IPO	Oct 05, 2001	Option/Short	No / Yes	EPS/Sales Surpr.	88.71% -	Trades		Volume	707,664	Change	-3.64%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-25	Initiated	Lake Street	Buy	$7
Oct-06-22	Initiated	Maxim Group	Buy	$3
Feb-17-21	Initiated	H.C. Wainwright	Buy	$15

Apr-06-26 09:00AM	Oncolytics Biotech Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer (GlobeNewswire)
Apr-01-26 09:00AM	Oncolytics Biotech Completes Domicile Change to the United States (GlobeNewswire) +9.58%
Mar-19-26 09:00AM	Oncolytics Biotech to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 (GlobeNewswire)
Mar-05-26 09:00AM	Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types (PR Newswire)
Mar-03-26 09:00AM	Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion (PR Newswire)
09:00AM	Loading…
Mar-02-26 09:00AM	Oncolytics Biotech Launches Randomized Colorectal Cancer Study (GlobeNewswire) -9.73%
Feb-25-26 09:00AM	Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 (PR Newswire)
Feb-24-26 10:58AM	Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge (PR Newswire) +6.60%
09:00AM	Oncolytics Biotech to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer (GlobeNewswire)
Feb-17-26 11:17AM	New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire) -7.79%
Feb-05-26 09:35AM	$207B Market Shift: The Race for Fast Track Approval in Oncology (PR Newswire) -7.04%
08:55AM	Oncolytics receives FDA Fast Track Designation for pelareorep (TipRanks)
Feb-04-26 08:50AM	Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer (GlobeNewswire)
Jan-30-26 10:36AM	$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium (PR Newswire)
10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire)
09:15AM	Loading…
Jan-28-26 09:15AM	Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment (PR Newswire)
Jan-27-26 10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire)
Jan-15-26 04:01PM	Oncolytics Biotech Announces Results of Special Meeting of Shareholders (GlobeNewswire) -7.33%
Jan-14-26 10:52AM	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff (PR Newswire)
09:00AM	Oncolytics Biotech Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics (GlobeNewswire)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire)
09:00AM	Oncolytics Biotech Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer (GlobeNewswire)
04:23AM	Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances (Insider Monkey)
Jan-10-26 09:05AM	Oncolytics outlines strategic rationale for proposal to change jurisdiction (TipRanks)
Jan-09-26 09:00AM	Oncolytics Biotech Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada (GlobeNewswire)
Jan-08-26 09:00AM	Oncolytics Biotech Provides Update on Intellectual Property Strategy and Patent Filings (Business Wire)
Jan-07-26 10:32AM	How $594B in Precision Tech is Cracking the Metastatic Cancer Code (PR Newswire)
09:00AM	Oncolytics Biotech Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen OReilly, Dr. Neil Segal, and Dr. Van Morris (Business Wire)
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire) +12.68%
09:00AM	Loading…
09:00AM	Oncolytics Biotech Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer (Business Wire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Dec-09-25 06:00PM	Oncolytics Biotech Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada (Business Wire)
Dec-03-25 09:35AM	Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-20-25 04:05PM	Oncolytics Biotech Provides Update on Special Meeting of Shareholders (Business Wire)
Nov-19-25 12:00PM	All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy (Zacks)
09:00AM	Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer (Business Wire)
Nov-04-25 08:00AM	Oncolytics Biotech Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy (Business Wire) -11.48%
Oct-28-25 07:30AM	Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care (PR Newswire)
Oct-20-25 09:00AM	Oncolytics Biotech Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada (PR Newswire)
Sep-29-25 08:30AM	Oncolytics Biotech Announces Update for Potential First-Line Pancreatic Cancer Registration Study (PR Newswire) +9.30%
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
07:00AM	Oncolytics Biotech Provides Update on GOBLET Study Progress and U.S. Site Expansion (PR Newswire)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire) +20.75%
07:00AM	Oncolytics Biotech Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions (PR Newswire)
Sep-02-25 09:30AM	Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands (PR Newswire) +10.58%
09:10AM	Oncolytics Biotech Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors (PR Newswire)
Aug-31-25 08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire)
08:30AM	Oncolytics Biotech Announces Upcoming Investor Conferences in September (PR Newswire)
Aug-14-25 12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire) -7.81%
12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-11-25 04:55PM	Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders (PR Newswire)
Aug-08-25 09:05AM	Oncolytics Biotech Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep (PR Newswire) -6.20%
09:00AM	Oncolytics Biotech Announces Voluntary Delisting from the Toronto Stock Exchange (PR Newswire)
Aug-05-25 08:30AM	Oncolytics Biotech Announces Upcoming Annual General Meeting and Second Quarter Financial Results (PR Newswire) +7.58%
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire) -6.42%
08:30AM	Oncolytics Biotech to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End (PR Newswire)
Jul-23-25 09:39AM	Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential (PR Newswire)
09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-22-25 03:32PM	Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules (PR Newswire)
Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire) +10.62% +5.60%
08:30AM	Oncolytics Biotech Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types (PR Newswire)
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire) -7.08%
08:30AM	Oncolytics Biotech to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers (PR Newswire)
Jul-08-25 08:30AM	Oncolytics Biotech Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies (PR Newswire) +23.76%
Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire)
07:00AM	Oncolytics Biotech Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy (PR Newswire)
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) +5.79%
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -6.74%
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire) +10.76%
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire)
09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-11-25 07:00AM	Oncolytics Biotech Names New CEO to Accelerate Momentum in Immunotherapy Programs (PR Newswire) +34.10%
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
07:00AM	Oncolytics Biotech to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities (PR Newswire)
May-15-25 03:15AM	Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-14-25 04:01PM	Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical Momentum (PR Newswire)
May-06-25 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights (PR Newswire) -6.42%
May-01-25 11:04AM	New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty (PR Newswire)
Apr-24-25 07:00AM	Oncolytics Biotech to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action (PR Newswire)
Apr-14-25 10:15AM	With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz (PR Newswire) -5.28%
Apr-10-25 06:09PM	Oncolytics Biotech Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital (PR Newswire) +24.56%
07:00AM	Oncolytics Biotech and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers (PR Newswire)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
02:03AM	Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ... (GuruFocus.com)
Mar-07-25 07:00AM	Oncolytics Biotech Reports Highlights and Financial Results for Q4 and Year-End 2024 (PR Newswire) -6.29%
Mar-05-25 09:35AM	Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +13.52%
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-25-25 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights (PR Newswire)
Feb-19-25 10:10AM	Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire)
07:00AM	Oncolytics Biotech Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 (PR Newswire)
Feb-18-25 07:00AM	Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer (PR Newswire)
Feb-14-25 05:15PM	Oncolytics Biotech Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (PR Newswire)
Feb-07-25 09:24PM	Oncolytics Biotech Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence (PR Newswire)
Feb-05-25 12:00PM	Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire) +5.26%
07:00AM	Oncolytics Biotech to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium (PR Newswire)
Jan-16-25 11:17AM	German PEI approves enrolment in cohort 5 of Oncolytics pancreatic cancer trial (Clinical Trials Arena)

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parsons James T.	Director	Mar 11 '26	Buy	1.03	10,000	10,300	41,849	Mar 13 08:00 AM
Kelly Jared	Chief Executive Officer	Mar 12 '26	Buy	0.96	5,050	4,848	114,050	Mar 13 08:00 AM
Kelly Jared	Chief Executive Officer	Feb 12 '26	Buy	0.84	29,500	24,839	109,000	Feb 13 07:00 AM
Kelly Jared	Chief Executive Officer	Feb 11 '26	Buy	0.84	5,600	4,682	79,500	Feb 13 07:00 AM
Look Kirk	Chief Financial Officer	Feb 12 '26	Buy	0.84	12,000	10,104	287,515	Feb 13 07:00 AM
Pisano Wayne	Director	Feb 12 '26	Buy	0.84	30,000	25,338	492,414	Feb 13 07:00 AM
Heineman Thomas Charles	Chief Medical Officer	Feb 12 '26	Buy	0.83	12,132	10,033	282,818	Feb 13 07:00 AM
Brown Deborah Margaret	Director	Feb 12 '26	Buy	0.85	25,000	21,240	109,851	Feb 13 07:00 AM
Hagerman Allison	VP, Product Development	Feb 12 '26	Buy	0.83	10,000	8,298	115,059	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Feb 11 '26	Buy	0.83	60,000	49,590	526,991	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Feb 12 '26	Buy	0.85	40,000	33,864	566,991	Feb 13 07:00 AM
Aromando Andrew	Chief Business Officer	Feb 11 '26	Buy	0.86	29,600	25,418	55,100	Feb 13 07:00 AM
Andrews Patricia S	Director	Feb 12 '26	Buy	0.86	35,400	30,292	78,128	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Jan 16 '26	Buy	1.04	100,000	103,770	466,991	Jan 20 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONCY

Oncolytics Biotech, Inc

Upgrade your Finviz experience